H.R. 8857, Pharmaceutical Price Protection Carve-out. Quorum's AI analysis reads it as a net cost — and names who bears it.
H.R. 8857 · Net cost
What it does
This bill modifies Medicare's drug price negotiation program to give a new class of drugs called 'engineered cyclic peptides' an 11-year exclusion period before they can be subject to price negotiation, instead of the standard 7-year period. Engineered cyclic peptides are synthetic, lab-designed drugs composed of amino acids in a ring structure, developed using genetic screening, and taken orally or inhaled. The change applies immediately to future drug lists.
The analysis names pharmaceutical manufacturers — and 2 more groups — among the beneficiaries.
The cost
The 11-year exclusion period is 57% longer than the standard 7-year period, creating a significant window during which engineered cyclic peptides will command premium prices without Medicare negotiation pressure.
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Joseph Morelle. Cosponsored by August Pfluger, Josh Gottheimer and Thomas Kean.